STOCK TITAN
  1. Home
  2. Sec-filings
  3. SNY
  4. [6-K] Sanofi Current Report (Foreign Issuer)

[6-K] Sanofi Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary

Sanofi furnished a Form 6‑K providing H1 2025 condensed consolidated results and updates. The company lost control of Opella on April 30, 2025; from May 1, 2025 OPAL JV Co is accounted for using the equity method. H1 operating cash flows reflect routine items, including income tax paid of €1,355 million, interest paid of €206 million, and interest received of €170 million.

Financing and liabilities were active across the period. As of June 30, 2025, current other bank borrowings included €4,535 million related to the US commercial paper program and €230 million related to the French program, while a financing cash‑flow line mainly comprised the US commercial paper program of €3,353 million (vs €6,060 million in H1 2024). Net debt metrics exclude lease liabilities of €1,776 million. The liability for royalties payable to Sobi on US Beyfortus net sales was €1,756 million, with nominal payments estimated at €1,027 million within one to five years and €2,293 million thereafter. The period included impairment losses of €210 million linked to R&D projects, a €17 million tax expense from Pillar Two, and an €88 million tax expense tied to the gain on the Opella deconsolidation.

Sanofi ha presentato un Form 6-K contenente i risultati condensati consolidati del primo semestre 2025 e aggiornamenti. L'azienda ha perso il controllo di Opella il 30 aprile 2025; dal 1 maggio 2025 OPAL JV Co viene contabilizzata utilizzando il metodo del patrimonio netto. I flussi di cassa operativi del primo semestre riflettono elementi ordinari, tra cui l'imposta sul reddito pagata di €1.355 milioni, gli interessi pagati di €206 milioni e gli interessi ricevuti di €170 milioni.

Finanziamenti e passività sono stati attivi durante il periodo. Al 30 giugno 2025, i prestiti bancari correnti e altri importi correlati includevano €4.535 milioni relativi al programma di commercial paper statunitense e €230 milioni relativi al programma francese, mentre una linea di flusso di cassa da finanziamento era principalmente costituita dal programma di commercial paper statunitense di €3.353 milioni (rispetto a €6.060 milioni nell'H1 2024). Le metriche di debito netto escludono le passività per leasing di €1.776 milioni. La passività per royalties dovute a Sobi sui ricavi netti USA di Beyfortus ammontava a €1.756 milioni, con pagamenti nominali stimati di €1.027 milioni entro uno e cinque anni e €2.293 milioni oltre. Il periodo ha incluso perdite di svalutazione di €210 milioni legate a progetti di R&D, un onere fiscale di €17 milioni legato al Pillar Two, e un onere fiscale di €88 milioni associato al guadagno derivante dalla deconsolidazione di Opella.

Sanofi presentó un Form 6-K que contiene los resultados condensados del primer semestre de 2025 y actualizaciones. La empresa perdió el control de Opella el 30 de abril de 2025; a partir del 1 de mayo de 2025 OPAL JV Co se contabiliza mediante el método de participación. Los flujos de efectivo operativos del semestre reflejan rubros rutinarios, incluyendo el impuesto a las ganancias pagado de 1.355 millones de euros, intereses pagados de 206 millones y intereses recibidos de 170 millones.

La financiación y los pasivos estuvieron activos durante el periodo. Al 30 de junio de 2025, los préstamos bancarios corrientes y otros incluían 4.535 millones de euros relacionados con el programa de papel comercial de EE. UU. y 230 millones relacionados con el programa francés, mientras que una línea de flujo de efectivo de financiación consistía principalmente en el programa de papel comercial de EE. UU. de 3.353 millones (frente a 6.060 millones en el H1 2024). Las métricas de deuda neta excluyen los pasivos por arrendamientos de 1.776 millones. La obligación por regalías debidas a Sobi sobre las ventas netas en EE. UU. de Beyfortus fue de 1.756 millones, con pagos nominales estimados de 1.027 millones dentro de uno a cinco años y 2.293 millones posteriormente. El periodo incluyó pérdidas por deterioro de 210 millones vinculadas a proyectos de I+D, un gasto tributario de 17 millones por Pillar Two y un gasto fiscal de 88 millones ligado a la ganancia por la desconsolidación de Opella.

Sanofi는 2025년 상반기 요약 연결 실적 및 업데이트를 제공하는 Form 6-K를 제출했습니다. 회사는 2025년 4월 30일에 Opella에 대한 지배력을 상실했습니다; 2025년 5월 1일부터 OPAL JV Co는 지분법으로 회계 처리됩니다. 상반기 영업현금흐름은 routine 항목을 반영하며, 법인세 납부액은 13억 5500만 유로, 이자지급은 2억 6만 유로, 이자수취는 1억 7000만 유로입니다.

기간 동안 조달과 부채가 활성화되었습니다. 2025년 6월 30일 기준으로 현재의 기타 은행차입은 미국 상업지시권 프로그램 관련 45억 3천만 유로와 프랑스 프로그램 관련 2.3억 유로를 포함했고, 자금흐름상의 금융 현금흐름 항목은 주로 미국 상업지시권 프로그램 33억 5천만 유로로 구성되었습니다(전년 동기 H1 2024의 60억 6천만 유로 대비). 순부채 지표는 리스부채 17억 7600만 유로를 제외합니다. 미국 Beyfortus 순매출에 대한 Sobi에 대한 로열티 부채는 17억 5600만 유로였고, 1~5년 내에 10억 2700만 유로, 그 이후에 22억 9300만 유로의 명목 지급이 추정됩니다. 해당 기간에는 연구개발(R&D) 프로젝트와 관련된 impairment 손실 2억 1천만 유로, Pillar Two로 인한 1천700만 유로의 세금비용, Opella의 소유권 제거로 인한 이익과 관련된 8천80만 유로의 세금비용이 포함되었습니다.

Sanofi a fourni un Form 6-K présentant les résultats consolidés condensés du premier semestre 2025 et des mises à jour. La société a perdu le contrôle d'Opella le 30 avril 2025; à compter du 1er mai 2025, OPAL JV Co est comptabilisée selon la méthode de mise en équivalence. Les flux de trésorerie opérationnels du 1er semestre reflètent des éléments routiniers, dont l’impôt sur les sociétés payé de 1 355 millions d’euros, les intérêts payés de 206 millions et les intérêts reçus de 170 millions.

Le financement et les passifs ont été actifs au cours de la période. Au 30 juin 2025, les emprunts bancaires courants et autres comprenaient 4 535 millions d’euros liés au programme de commercial paper américain et 230 millions liés au programme français, tandis qu’une ligne de flux de trésorerie de financement était principalement constituée par le programme de commercial paper américain de 3 353 millions (par rapport à 6 060 millions au S1 2024). Les mesures de dette nette excluent les passifs de location de 1 776 millions. La dette sous forme de redevances dues à Sobi sur les ventes nettes américaines de Beyfortus s’élevait à 1 756 millions d’euros, avec des paiements nominaux estimés à 1 027 millions dans un à cinq ans et à 2 293 millions par la suite. La période a inclus des pertes de valeur liées à des projets de R&D pour 210 millions, une dépense fiscale Pillar Two de 17 millions et une dépense fiscale de 88 millions liée au gain sur la déconsolidation d’Opella.

Sanofi hat ein Form 6-K vorgelegt, das die konsolidierten Zwischenergebnisse für das erste Halbjahr 2025 sowie Updates enthält. Das Unternehmen hat die Kontrolle über Opella am 30. April 2025 verloren; ab dem 1. Mai 2025 wird OPAL JV Co mit der Eigenkapitalmethode bewertet. Die operativen Cashflows im ersten Halbjahr spiegeln routinemäßige Posten wider, einschließlich der gezahlten Körperschaftsteuer von 1.355 Mio. €, der gezahlten Zinsen von 206 Mio. € und der erhaltenen Zinsen von 170 Mio. €.

Finanzierung und Verbindlichkeiten waren im Zeitraum aktiv. Zum 30. Juni 2025 umfassten laufende Sonstige Bankdarlehen €4.535 Mio. im Zusammenhang mit dem US Commercial Paper-Programm und €230 Mio. im Zusammenhang mit dem französischen Programm, während eine Finanzierungscashflow-Position im Wesentlichen dem US-Commercial-Paper-Programm von €3.353 Mio. entsprach (gegenüber €6.060 Mio. im H1 2024). Die Nettoverschuldungskennzahlen schließen Leasingverbindlichkeiten in Höhe von €1.776 Mio. aus. Die Royalty-Verbindlichkeit zugunsten von Sobi auf die US-Umsätze von Beyfortus betrug €1.756 Mio., mit nominal geschätzten Zahlungen von €1.027 Mio. innerhalb von eins bis fünf Jahren und €2.293 Mio. danach. Der Zeitraum enthielt Impairment-Verluste von €210 Mio. in Zusammenhang mit F&E-Projekten, eine Pillar-Two-Steuer von €17 Mio. und eine Steuerbelastung von €88 Mio. im Zusammenhang mit dem Gewinn aus der Entkonsolidierung von Opella.

سانوفي قد قدمت نموذج 6-K يوفر نتائج مركّزة للنصف الأول من عام 2025 وتحديثات. الشركة فقدت السيطرة على Opella في 30 أبريل 2025؛ اعتباراً من 1 مايو 2025، يتم احتساب شركة OPAL JV باستخدام طريقة حقوق الملكية. التدفقات النقدية التشغيلية للنصف الأول تعكس بنود روتينية، بما في ذلك ضريبة الدخل المدفوعة بمقدار 1,355 مليون يورو، والفائدة المدفوعة بمقدار 206 ملايين، والفائدة المستلمة بمقدار 170 مليوناً.

كان التمويل والالتزامات نشطة خلال الفترة. حتى 30 يونيو 2025، شملت القروض المصرفية الجارية وأرصدة أخرى 4,535 مليون يورو تتعلق ببرنامج الأوراق التجارية الأمريكية و230 مليون يورو تتعلق بالبرنامج الفرنسي، بينما كانت خط التدفقات النقدية للتمويل يتكوّن بشكل رئيسي من برنامج الأوراق التجارية الأمريكية بمقدار 3,353 مليون يورو (مقابل 6,060 مليون يورو في النصف الأول 2024). تستثني مقاييس الدين الصافي التزامات التأجير البالغة 1,776 مليون يورو. كانت الالتزامات الخاصة بالحقوق الملكية لسوبي على مبيعات بايرفورDS الأمريكية 1,756 مليون يورو، مع تقدير سداد Nominal قدره 1,027 مليون يورو خلال سنة واحد إلى خمس سنوات و2,293 مليون يورو بعد ذلك. تضمنت الفترة خسائر انخفاض قيمة قدرها 210 ملايين يورو مرتبطة بمشروعات البحث والتطوير، وتكلفة ضريبية Pillar Two قدرها 17 مليون يورو، وتكلفة ضريبية قدرها 88 مليون يورو مرتبطة بالربح الناتج عن إلغاء تجميع Opella.

Positive
  • None.
Negative
  • None.

Insights

Structural changes and liability details; core thesis unchanged.

Sanofi reclassified Consumer Healthcare via the loss of control of Opella on April 30, 2025, moving OPAL JV Co to equity method from May 1, 2025. This is a structural shift in reporting rather than a cash transaction, but it changes how earnings from the JV are reflected.

Balance sheet and cash‑flow items highlight funding and obligations. Current other bank borrowings include the US commercial paper program of €4,535 million and the French program of €230 million as of June 30, 2025. The liability for royalties payable to Sobi on US Beyfortus net sales stands at €1,756 million, with disclosed nominal schedules across future periods.

H1 also included R&D‑linked impairments of €210 million and tax items such as €17 million from Pillar Two and €88 million related to the Opella deconsolidation. Actual impact on results depends on subsequent performance and JV contributions disclosed in future reports.

Sanofi ha presentato un Form 6-K contenente i risultati condensati consolidati del primo semestre 2025 e aggiornamenti. L'azienda ha perso il controllo di Opella il 30 aprile 2025; dal 1 maggio 2025 OPAL JV Co viene contabilizzata utilizzando il metodo del patrimonio netto. I flussi di cassa operativi del primo semestre riflettono elementi ordinari, tra cui l'imposta sul reddito pagata di €1.355 milioni, gli interessi pagati di €206 milioni e gli interessi ricevuti di €170 milioni.

Finanziamenti e passività sono stati attivi durante il periodo. Al 30 giugno 2025, i prestiti bancari correnti e altri importi correlati includevano €4.535 milioni relativi al programma di commercial paper statunitense e €230 milioni relativi al programma francese, mentre una linea di flusso di cassa da finanziamento era principalmente costituita dal programma di commercial paper statunitense di €3.353 milioni (rispetto a €6.060 milioni nell'H1 2024). Le metriche di debito netto escludono le passività per leasing di €1.776 milioni. La passività per royalties dovute a Sobi sui ricavi netti USA di Beyfortus ammontava a €1.756 milioni, con pagamenti nominali stimati di €1.027 milioni entro uno e cinque anni e €2.293 milioni oltre. Il periodo ha incluso perdite di svalutazione di €210 milioni legate a progetti di R&D, un onere fiscale di €17 milioni legato al Pillar Two, e un onere fiscale di €88 milioni associato al guadagno derivante dalla deconsolidazione di Opella.

Sanofi presentó un Form 6-K que contiene los resultados condensados del primer semestre de 2025 y actualizaciones. La empresa perdió el control de Opella el 30 de abril de 2025; a partir del 1 de mayo de 2025 OPAL JV Co se contabiliza mediante el método de participación. Los flujos de efectivo operativos del semestre reflejan rubros rutinarios, incluyendo el impuesto a las ganancias pagado de 1.355 millones de euros, intereses pagados de 206 millones y intereses recibidos de 170 millones.

La financiación y los pasivos estuvieron activos durante el periodo. Al 30 de junio de 2025, los préstamos bancarios corrientes y otros incluían 4.535 millones de euros relacionados con el programa de papel comercial de EE. UU. y 230 millones relacionados con el programa francés, mientras que una línea de flujo de efectivo de financiación consistía principalmente en el programa de papel comercial de EE. UU. de 3.353 millones (frente a 6.060 millones en el H1 2024). Las métricas de deuda neta excluyen los pasivos por arrendamientos de 1.776 millones. La obligación por regalías debidas a Sobi sobre las ventas netas en EE. UU. de Beyfortus fue de 1.756 millones, con pagos nominales estimados de 1.027 millones dentro de uno a cinco años y 2.293 millones posteriormente. El periodo incluyó pérdidas por deterioro de 210 millones vinculadas a proyectos de I+D, un gasto tributario de 17 millones por Pillar Two y un gasto fiscal de 88 millones ligado a la ganancia por la desconsolidación de Opella.

Sanofi는 2025년 상반기 요약 연결 실적 및 업데이트를 제공하는 Form 6-K를 제출했습니다. 회사는 2025년 4월 30일에 Opella에 대한 지배력을 상실했습니다; 2025년 5월 1일부터 OPAL JV Co는 지분법으로 회계 처리됩니다. 상반기 영업현금흐름은 routine 항목을 반영하며, 법인세 납부액은 13억 5500만 유로, 이자지급은 2억 6만 유로, 이자수취는 1억 7000만 유로입니다.

기간 동안 조달과 부채가 활성화되었습니다. 2025년 6월 30일 기준으로 현재의 기타 은행차입은 미국 상업지시권 프로그램 관련 45억 3천만 유로와 프랑스 프로그램 관련 2.3억 유로를 포함했고, 자금흐름상의 금융 현금흐름 항목은 주로 미국 상업지시권 프로그램 33억 5천만 유로로 구성되었습니다(전년 동기 H1 2024의 60억 6천만 유로 대비). 순부채 지표는 리스부채 17억 7600만 유로를 제외합니다. 미국 Beyfortus 순매출에 대한 Sobi에 대한 로열티 부채는 17억 5600만 유로였고, 1~5년 내에 10억 2700만 유로, 그 이후에 22억 9300만 유로의 명목 지급이 추정됩니다. 해당 기간에는 연구개발(R&D) 프로젝트와 관련된 impairment 손실 2억 1천만 유로, Pillar Two로 인한 1천700만 유로의 세금비용, Opella의 소유권 제거로 인한 이익과 관련된 8천80만 유로의 세금비용이 포함되었습니다.

Sanofi a fourni un Form 6-K présentant les résultats consolidés condensés du premier semestre 2025 et des mises à jour. La société a perdu le contrôle d'Opella le 30 avril 2025; à compter du 1er mai 2025, OPAL JV Co est comptabilisée selon la méthode de mise en équivalence. Les flux de trésorerie opérationnels du 1er semestre reflètent des éléments routiniers, dont l’impôt sur les sociétés payé de 1 355 millions d’euros, les intérêts payés de 206 millions et les intérêts reçus de 170 millions.

Le financement et les passifs ont été actifs au cours de la période. Au 30 juin 2025, les emprunts bancaires courants et autres comprenaient 4 535 millions d’euros liés au programme de commercial paper américain et 230 millions liés au programme français, tandis qu’une ligne de flux de trésorerie de financement était principalement constituée par le programme de commercial paper américain de 3 353 millions (par rapport à 6 060 millions au S1 2024). Les mesures de dette nette excluent les passifs de location de 1 776 millions. La dette sous forme de redevances dues à Sobi sur les ventes nettes américaines de Beyfortus s’élevait à 1 756 millions d’euros, avec des paiements nominaux estimés à 1 027 millions dans un à cinq ans et à 2 293 millions par la suite. La période a inclus des pertes de valeur liées à des projets de R&D pour 210 millions, une dépense fiscale Pillar Two de 17 millions et une dépense fiscale de 88 millions liée au gain sur la déconsolidation d’Opella.

Sanofi hat ein Form 6-K vorgelegt, das die konsolidierten Zwischenergebnisse für das erste Halbjahr 2025 sowie Updates enthält. Das Unternehmen hat die Kontrolle über Opella am 30. April 2025 verloren; ab dem 1. Mai 2025 wird OPAL JV Co mit der Eigenkapitalmethode bewertet. Die operativen Cashflows im ersten Halbjahr spiegeln routinemäßige Posten wider, einschließlich der gezahlten Körperschaftsteuer von 1.355 Mio. €, der gezahlten Zinsen von 206 Mio. € und der erhaltenen Zinsen von 170 Mio. €.

Finanzierung und Verbindlichkeiten waren im Zeitraum aktiv. Zum 30. Juni 2025 umfassten laufende Sonstige Bankdarlehen €4.535 Mio. im Zusammenhang mit dem US Commercial Paper-Programm und €230 Mio. im Zusammenhang mit dem französischen Programm, während eine Finanzierungscashflow-Position im Wesentlichen dem US-Commercial-Paper-Programm von €3.353 Mio. entsprach (gegenüber €6.060 Mio. im H1 2024). Die Nettoverschuldungskennzahlen schließen Leasingverbindlichkeiten in Höhe von €1.776 Mio. aus. Die Royalty-Verbindlichkeit zugunsten von Sobi auf die US-Umsätze von Beyfortus betrug €1.756 Mio., mit nominal geschätzten Zahlungen von €1.027 Mio. innerhalb von eins bis fünf Jahren und €2.293 Mio. danach. Der Zeitraum enthielt Impairment-Verluste von €210 Mio. in Zusammenhang mit F&E-Projekten, eine Pillar-Two-Steuer von €17 Mio. und eine Steuerbelastung von €88 Mio. im Zusammenhang mit dem Gewinn aus der Entkonsolidierung von Opella.

سانوفي قد قدمت نموذج 6-K يوفر نتائج مركّزة للنصف الأول من عام 2025 وتحديثات. الشركة فقدت السيطرة على Opella في 30 أبريل 2025؛ اعتباراً من 1 مايو 2025، يتم احتساب شركة OPAL JV باستخدام طريقة حقوق الملكية. التدفقات النقدية التشغيلية للنصف الأول تعكس بنود روتينية، بما في ذلك ضريبة الدخل المدفوعة بمقدار 1,355 مليون يورو، والفائدة المدفوعة بمقدار 206 ملايين، والفائدة المستلمة بمقدار 170 مليوناً.

كان التمويل والالتزامات نشطة خلال الفترة. حتى 30 يونيو 2025، شملت القروض المصرفية الجارية وأرصدة أخرى 4,535 مليون يورو تتعلق ببرنامج الأوراق التجارية الأمريكية و230 مليون يورو تتعلق بالبرنامج الفرنسي، بينما كانت خط التدفقات النقدية للتمويل يتكوّن بشكل رئيسي من برنامج الأوراق التجارية الأمريكية بمقدار 3,353 مليون يورو (مقابل 6,060 مليون يورو في النصف الأول 2024). تستثني مقاييس الدين الصافي التزامات التأجير البالغة 1,776 مليون يورو. كانت الالتزامات الخاصة بالحقوق الملكية لسوبي على مبيعات بايرفورDS الأمريكية 1,756 مليون يورو، مع تقدير سداد Nominal قدره 1,027 مليون يورو خلال سنة واحد إلى خمس سنوات و2,293 مليون يورو بعد ذلك. تضمنت الفترة خسائر انخفاض قيمة قدرها 210 ملايين يورو مرتبطة بمشروعات البحث والتطوير، وتكلفة ضريبية Pillar Two قدرها 17 مليون يورو، وتكلفة ضريبية قدرها 88 مليون يورو مرتبطة بالربح الناتج عن إلغاء تجميع Opella.

赛诺菲提交了6-K表，提供2025年上半年合并简要业绩及更新。公司于2025年4月30日丧失对< b>Opella的控制；自2025年5月1日起，OPAL JV Co 将采用权益法进行入账。上半年经营现金流反映日常事项，包括已缴纳的企业所得税13.55亿欧元、已支付的利息2.06亿欧元、已收到的利息1.70亿欧元。

在该期间，融资与负债活跃。至2025年6月30日，当前其他银行借款包含与美国商业票据计划相关的45.35亿欧元和与法国计划相关的2.30亿欧元，而融资现金流主要包括美国商业票据计划的33.53亿欧元（与2024年上半年的60.60亿欧元相比）。净债务指标不含1.776亿欧元的租赁负债。对Sobi的就美国贝福特斯(Beyfortus)净销售额的特许权使用费负债为17.56亿欧元，名义支付预计在1到5年内为10.27亿欧元，且此后为22.93亿欧元。该期间包括与研发项目相关的2100万欧元减值损失、Pillar Two 1200万欧元的税费以及与Opella撤并带来的收益相关的8800万欧元税费。

false0001121404--12-312025-06-30Q2These unaudited condensed half year consolidated financial statements as of June 30, 2025 should be read in conjunction with Sanofi’s audited consolidated financial statements as of December 31, 2024.Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.This line comprises the impact of the derecognition of the non-controlling interests in Opella (see Note B.1.).For 2025, this line comprises the impact of the issuance of restricted shares to former employees of Opella subsequent to the date on which Sanofi lost control of Opella.See Note B.8.2. (for amounts relating to 2024, see Note D.15.4. to the consolidated financial statements for the year ended December 31, 2024).For the six months ended June 30, 2025, this amount includes €(667) million in respect of cash and cash equivalents held by Opella as of April 30, 2025.For the six months ended June 30, 2025, this line item mainly comprises a commercial paper program in the United States for €3,353 million, compared with €6,060 million in the six months ended June 30, 2024. This line item also includes realized foreign exchange gains and losses on cash and cash equivalents in non-functional currencies, mainly the US dollar, and on derivatives used to manage them.For 2024, this line comprises the impact of the issuance of restricted shares to former employees of EUROAPI subsequent to the date on which Sanofi lost control of EUROAPI.Includes non-current financial assets.This line item includes contributions paid to pension funds (see Note B.12.).This line item mainly comprises unrealized foreign exchange gains and losses arising on the remeasurement of monetary items in non-functional currencies and on instruments used to hedge such itemsOf which: June 30, 2025 (6 months) June 30, 2024 (6 months) (a) •Income tax paid (1,355) (1,434) •Interest paid (206) (320) •Interest received 170 261 •Dividends received from non-consolidated entities 5 —This line item includes payments made in respect of contingent consideration identified and recognized as a liability in business combinations. For the six months ended June 30, 2025, this line item includes the net cash outflow arising from the acquisition of Dren-0201 (see Note B.1.2.). For the six months ended June 30, 2024 it includes the net cash outflow arising from the acquisition of Inhibrx, Inc.For the six months ended June 30, 2025 and June 30, 2024, this line item mainly comprises proceeds from disposals of (i) assets and businesses due to portfolio rationalization, and (ii) equity and debt instruments.Currency translation differences on foreign subsidiaries are mainly due to the appreciation of the US dollar.Includes reclassifications to profit or loss: €2 million in the first half of 2025, immaterial in the first half of 2024.Includes reclassifications to profit or loss: immaterial over all periods.With effect from May 1, 2025, OPAL JV Co is accounted for using the equity method following the loss of control of Opella by Sanofi on April 30, 2025.In October 2024, Sanofi raised its investment in EUROAPI by €200 million in the form of a perpetual subordinated hybrid bond. The fair value of this investment as of June 30, 2025 was €189 million (and was also €189 million as of December 31, 2024).Includes loans to joint ventures and associates.Figures for 2024 comparative periods have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.For the six months ended June 30, 2025, these amounts include transactions between Sanofi and OPAL JV Co for the period from May 1, 2025 through June 30, 2025.Joint venture. MSP Vaccine Company owns 100% of MCM Vaccine BV.Joint venture.Weighting between (i) fair value determined using the Monte Carlo model and (ii) market price of Sanofi shares at the date of grant, adjusted for dividends expected during the vesting period.Quoted market price per share at the date of grant, adjusted for dividends expected during the vesting period.Net debt does not include lease liabilities, which amounted to €1,776 million as of June 30, 2025 and €1,906 million as of December 31, 2024. Following the loss of control of Opella, Sanofi holds 48.2% of OPAL JV Co (CD&R holds 50% and Bpifrance holds 1.8%), see Note B.1.. As of June 30, 2025, the investment includes a €241 million loan to OPAL JV Co being in substance part of the investment.The investment in EUROAPI includes an impairment loss booked in prior years determined by reference to the quoted market price (€2.89 as of June 30, 2025, and €2.88 as of December 31, 2024).In the case of “Provisions for pensions and other post-employment benefits”, the “Increases in provisions” line corresponds to rights vesting in employees during the period, and past service cost; the “Provisions utilized” line corresponds to contributions paid into pension funds and to beneficiaries; and the “Reversals of unutilized provisions” line corresponds to plan curtailments, settlements and amendments.For the first half of 2025, these lines include the net sales and operating income of Opella until the date of loss of control date (see Note B.1.).In 2025, this line includes an expense of €88 million related to the tax impact on the gain arising on the loss of control of Opella.Includes €1,756 million at June 30, 2025 relating to the liability for royalties payable to Sobi on net sales of Beyfortus in the United States ( see Note C.2. to the consolidated financial statements for the year ended December 31, 2024) . Given the method used to calculate royalties payable, an increase or decrease in sales forecasts would lead to a proportionate change in the amount of the liability. The nominal value of payments estimated to be due within more than one year but less than five years is €1,027 million; the nominal value of payments estimated to be due after more than five years is €2,293 million.As of January 1, 2025, this comprised a non-current portion of €569 million and a current portion of €72 million.Amounts mainly reported within the income statement line item “Fair value remeasurement of contingent consideration”.Joint ventures and associates with which Sanofi has entered into a strategic alliance.Excludes (i) restructuring costs and (ii) other adjustments attributable to non-controlling interests.The monitoring of impairment indicators for other intangible assets led to the recognition of impairment losses of €210 million in the first half of 2025 linked to research and development projects. As of June 30, 2024, this line includes a net reversal of impairment losses amounting to €371 million, mainly due to an increase in the expected recoverable amounts of certain marketed products and other rights.This line records the impact of the workdown of acquired inventories remeasured at fair value at the acquisition date.See Note B.16.See Note B.17.Carrying amount at the end of the reporting period.As of June 30, 2025, current other bank borrowings include €4,535 million related to the US commercial paper program and €230 million related to the Negotiable European Commercial Paper program in France. Includes actuarial gains/ (losses) related to Opella of €(4) million for the first half of 2025 and €(6) million for the first half of 2024.Includes the effects of (i) the change in discount rates (in a range between +0.40% and +0.65%) and (ii) the +0.10% change in the inflation rate in the United Kingdom in the first half of 2024.Includes the effects of (i) the change in discount rates (in a range between 0.00% and +0.30%) and (ii) the -0.30% change in the inflation rate in the United Kingdom in the first half of 2025.Mainly transfers to Current provisions and other current liabilities.Includes forward purchases with a notional amount of $1,000 million expiring in 2025, designated as a fair value hedge of the exposure of $1,000 million of bond issues to fluctuations in the EUR/USD spot rate. As of June 30, 2025, the fair value of these contracts represented a liability of €25 million, with €0 million credited to Other comprehensive income to recognize the hedging cost. Includes forward sales with a notional amount of $3,615 million expiring in 2025, designated as a hedge of Sanofi’s net investment in Bioverativ. As of June 30, 2025, the fair value of these forward contracts represented an asset of €77 million; the opposite entry was recognized in Other comprehensive income, with the impact on financial income and expense being immaterial. Comprises two cross currency swaps, (i) with a notional amount of $870 million, pay 4.16% receive EUR 2.50%, expiring 2029 and (ii) with a notional amount of $870 million, pay 4.53% receive EUR 3.00%, expiring 2032, designated as a fair value hedge of the exposure of an equivalent amount of cash & cash equivalents to fluctuations in the EUR/USD spot rate. As of June 30, 2025, the fair value of the swaps was an asset of €5 million, with €18 million debited to Other comprehensive income under the cost of hedging accounting treatment. Revenues generated from the manufacture of Consumer Healthcare products on behalf of Opella entities. Until April 30, 2025, Opella entities were within the scope of discontinued operations (see Note B.1). With effect from May 1, 2025, Opella entities are treated as related parties in accordance with IAS24 (see Note B.5.).This line mainly comprises revenues received under agreements for Sanofi to provide manufacturing services to third parties.Consumer Healthcare activities not transferred on the effective date of loss of control of Opella. These are primarily (i) hospital sales of Opella products in China, the transfer of which will be finalized no earlier than 2028; (ii) sales made by the dedicated entity Opella Russie, of which Sanofi continues to hold the capital (Sanofi is continuing to distribute Opella products in Russian territory under a distribution agreement signed in connection with the separation, the parties reserving the right to discuss the transfer of that entity during the term of the distribution agreement); and (iii) sales of the Gold Bond product range, which are continuing in the United States through the retained subsidiary Gold Bond LLC (holder of the associated worldwide property rights).Figures for 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.Rate calculated on the basis of the estimated effective tax rate for the full financial year (see Note A.2.).The difference between the French tax rate and tax rates applicable to foreign subsidiaries reflects the fact that Sanofi has operations in many countries, most of which have lower tax rates than France.For the six months ended June 30, 2025, this line includes a tax expense of €17 million, representing the estimated impact of Pillar Two based on Sanofi’s current understanding of Pillar Two rules, and €52 million for the six months ended June 30, 2024.Reflects new regulations implemented on the taxation of share cancellations in Article 95 of the French Finance Bill for 2025.This line consists of impairment losses and accelerated depreciation charges related to closed or divested sites (including leased sites), and gains or losses on divestments of assets arising from reorganization decisions made by Sanofi.Includes net gain/(loss) on interest rate and currency derivatives used to manage debt: €(25) million in the first half of 2025 and €(24) million in the first half of 2024.Includes net gain/(loss) on interest rate and currency derivatives used to manage cash and cash equivalents: €(4) million in the first half of 2025 and €(18) million in the first half of 2024.Primarily on provisions for environmental risks, restructuring provisions, and provisions for product-related risks (see Note B.12.).Includes a financial expense of €50 million for the six months ended June 30, 2025 and €176 million for the six months ended June 30, 2024 for the remeasurement of the liability recorded in the balance sheet for estimated future royalties on Beyfortus sales in the US. 0001121404 2025-06-30 0001121404 2024-12-31 0001121404 2025-01-01 2025-06-30 0001121404 2024-01-01 2024-06-30 0001121404 2024-07-01 2024-12-31 0001121404 2024-06-30 0001121404 2023-12-31 0001121404 2024-10-31 0001121404 2025-05-01 2025-06-30 0001121404 2025-01-01 0001121404 ifrs-full:EquityAttributableToOwnersOfParentMember 2025-01-01 2025-06-30 0001121404 ifrs-full:AdditionalPaidinCapitalMember 2025-01-01 2025-06-30 0001121404 ifrs-full:IssuedCapitalMember 2025-01-01 2025-06-30 0001121404 sny:ManufacturingAndSupplyMember sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 sny:OpellaMember 2025-01-01 2025-06-30 0001121404 sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 ifrs-full:OtherIntangibleAssetsMember 2025-01-01 2025-06-30 0001121404 sny:OpellaMember 2025-01-01 2025-06-30 0001121404 sny:CDRMember 2025-01-01 2025-06-30 0001121404 sny:OPALJVCoMember 2025-01-01 2025-06-30 0001121404 sny:EuroapiMember 2025-01-01 2025-06-30 0001121404 sny:BpifranceMember 2025-01-01 2025-06-30 0001121404 sny:AssociatesAndJointVenturesMember 2025-01-01 2025-06-30 0001121404 sny:WithMarketConditionMember srt:ChiefExecutiveOfficerMember sny:RestrictedSharePlan2025Member 2025-01-01 2025-06-30 0001121404 sny:WithMarketConditionMember sny:RestrictedSharePlan2025Member 2025-01-01 2025-06-30 0001121404 sny:WithoutMarketConditionMember sny:RestrictedSharePlan2025Member 2025-01-01 2025-06-30 0001121404 sny:RestrictedSharePlan2025Member 2025-01-01 2025-06-30 0001121404 sny:WithMarketConditionMember sny:ExcludingChiefExecutiveOfficerMember sny:RestrictedSharePlan2025Member 2025-01-01 2025-06-30 0001121404 sny:RestrictedSharesMember 2025-01-01 2025-06-30 0001121404 ifrs-full:AccumulatedOtherComprehensiveIncomeMember sny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember 2025-01-01 2025-06-30 0001121404 country:US sny:MeningitisTravelAndEndemicVaccinesMember sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 sny:OtherCountriesMember sny:MeningitisTravelAndEndemicVaccinesMember sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 sny:MeningitisTravelAndEndemicVaccinesMember sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 sny:OtherCountriesMember sny:IndustrialSalesMember sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 sny:IndustrialSalesMember sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 srt:EuropeMember sny:PolioPertussisHibVaccinesMember sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 country:US sny:PolioPertussisHibVaccinesMember sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 sny:OtherCountriesMember sny:PolioPertussisHibVaccinesMember sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 sny:PolioPertussisHibVaccinesMember sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 srt:EuropeMember sny:TzieldMember sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 country:US sny:TzieldMember sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 sny:OtherCountriesMember sny:TzieldMember sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 sny:TzieldMember sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 srt:EuropeMember sny:IndustrialSalesMember sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 country:US sny:IndustrialSalesMember sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 sny:OtherCountriesMember sny:SarclisaMember sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 sny:SarclisaMember sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 srt:EuropeMember sny:RezurockMember sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 country:US sny:RezurockMember sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 sny:OtherCountriesMember sny:RezurockMember sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 sny:RezurockMember sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 srt:EuropeMember sny:AubagioMember sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 country:US sny:AubagioMember sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 sny:OtherCountriesMember sny:AubagioMember sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 sny:AubagioMember sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 srt:EuropeMember sny:SarclisaMember sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 country:US sny:SarclisaMember sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 sny:OtherCountriesMember sny:CabliviMember sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 sny:CabliviMember sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 srt:EuropeMember sny:XenpozymeMember sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 country:US sny:XenpozymeMember sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 sny:OtherCountriesMember sny:XenpozymeMember sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 sny:XenpozymeMember sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 srt:EuropeMember sny:NexviazymeMember sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 country:US sny:NexviazymeMember sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 sny:OtherCountriesMember sny:NexviazymeMember sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 sny:NexviazymeMember sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 srt:EuropeMember sny:CabliviMember sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 country:US sny:CabliviMember sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 sny:OtherCountriesMember sny:DupixentMember sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 sny:DupixentMember sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 srt:EuropeMember sny:AltuviiioMember sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 country:US sny:AltuviiioMember sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 sny:OtherCountriesMember sny:AltuviiioMember sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 sny:AltuviiioMember sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 sny:OtherCountriesMember sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 srt:EuropeMember sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 country:US sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 sny:OtherCountriesMember sny:InfluenzaVaccinesMember sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 sny:InfluenzaVaccinesMember sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 srt:EuropeMember 2025-01-01 2025-06-30 0001121404 country:US 2025-01-01 2025-06-30 0001121404 sny:OtherCountriesMember 2025-01-01 2025-06-30 0001121404 srt:EuropeMember sny:RSVVaccinesMember sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 country:US sny:RSVVaccinesMember sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 sny:OtherCountriesMember sny:RSVVaccinesMember sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 sny:RSVVaccinesMember sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 srt:EuropeMember sny:InfluenzaVaccinesMember sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 country:US sny:InfluenzaVaccinesMember sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 srt:EuropeMember sny:MeningitisTravelAndEndemicVaccinesMember sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 srt:EuropeMember sny:DupixentMember sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 country:US sny:DupixentMember sny:BiopharmaSegmentMember 2025-01-01 2025-06-30 0001121404 ifrs-full:ReportableSegmentsMember 2025-01-01 2025-06-30 0001121404 sny:PensionsAndOtherPostEmploymentBenefitsMember ifrs-full:PlanAssetsMember 2025-01-01 2025-06-30 0001121404 sny:OtherOperatingIncomeExpenseMember sny:RegeneronMember 2025-01-01 2025-06-30 0001121404 sny:OtherOperatingIncomeExpenseMember ifrs-full:OtherRelatedPartiesMember 2025-01-01 2025-06-30 0001121404 sny:AntibodiesAllianceMember 2025-01-01 2025-06-30 0001121404 sny:CommercializationRelatedExpensesMember sny:AntibodiesAllianceMember 2025-01-01 2025-06-30 0001121404 sny:ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember sny:AntibodiesAllianceMember 2025-01-01 2025-06-30 0001121404 sny:OtherCountriesExcludingEuropeAndNorthAmericaMember 2025-01-01 2025-06-30 0001121404 country:CN 2025-01-01 2025-06-30 0001121404 country:FR 2025-01-01 2025-06-30 0001121404 ifrs-full:OperatingSegmentsMember 2025-01-01 2025-06-30 0001121404 sny:CertainWholesalersInTheUnitedStatesMember 2025-01-01 2025-06-30 0001121404 sny:CustomerOneMember 2025-01-01 2025-06-30 0001121404 sny:CustomerTwoMember 2025-01-01 2025-06-30 0001121404 sny:CustomerThreeMember 2025-01-01 2025-06-30 0001121404 ifrs-full:MaterialReconcilingItemsMember 2025-01-01 2025-06-30 0001121404 sny:ShareOfProfitOrLossFromCommercializationOfZaltrapMember sny:AntibodiesAllianceMember 2025-01-01 2025-06-30 0001121404 sny:CommercializationRelatedExpensesMember ifrs-full:OtherRelatedPartiesMember sny:RegeneronMember 2025-01-01 2025-06-30 0001121404 sny:PensionsAndOtherPostEmploymentBenefitsMember 2025-01-01 2025-06-30 0001121404 sny:PensionsAndOtherPostEmploymentBenefitsMember sny:OpellaBusinessMember 2025-01-01 2025-06-30 0001121404 ifrs-full:AllOtherSegmentsMember 2025-01-01 2025-06-30 0001121404 sny:ProvisionsForPensionsAndOtherPostemploymentBenefitsMember 2025-01-01 2025-06-30 0001121404 sny:ProvisionsForOtherLongTermBenefitsMember 2025-01-01 2025-06-30 0001121404 sny:NonCurrentRestructuringProvisionMember 2025-01-01 2025-06-30 0001121404 ifrs-full:MiscellaneousOtherProvisionsMember 2025-01-01 2025-06-30 0001121404 sny:ValueOnRedemptionMember 2025-01-01 2025-06-30 0001121404 sny:ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember 2025-01-01 2025-06-30 0001121404 sny:MSDContingentConsiderationEuropeanVaccinesBusinessMember 2025-01-01 2025-06-30 0001121404 sny:OtherLiabilities1Member 2025-01-01 2025-06-30 0001121404 ifrs-full:GrossCarryingAmountMember sny:AcquiredResearchAndDevelopmentMember 2025-01-01 2025-06-30 0001121404 ifrs-full:GrossCarryingAmountMember sny:ProductsTrademarksAndOtherRightsMember 2025-01-01 2025-06-30 0001121404 ifrs-full:GrossCarryingAmountMember ifrs-full:ComputerSoftwareMember 2025-01-01 2025-06-30 0001121404 ifrs-full:GrossCarryingAmountMember 2025-01-01 2025-06-30 0001121404 ifrs-full:NoncontrollingInterestsMember 2025-01-01 2025-06-30 0001121404 ifrs-full:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-06-30 0001121404 ifrs-full:RetainedEarningsMember 2025-01-01 2025-06-30 0001121404 ifrs-full:AggregatedIndividuallyImmaterialAssociatesMember 2025-01-01 2025-06-30 0001121404 sny:MSPVaccineCompanyMember 2025-01-01 2025-06-30 0001121404 sny:InfraservGmbhAndCoHochstKGMember 2025-01-01 2025-06-30 0001121404 sny:StockOptionPlanMember sny:ExercisePriceRangeThreeMember 2025-01-01 2025-06-30 0001121404 sny:StockOptionPlanMember sny:ExercisePriceRangeTwoMember 2025-01-01 2025-06-30 0001121404 sny:StockOptionPlanMember sny:ExercisePriceRangeFourMember 2025-01-01 2025-06-30 0001121404 sny:OthersCounterpartyMember 2025-01-01 2025-06-30 0001121404 sny:CommercialPaperProgramInFranceMember sny:SanofiEuroMediumTermNotesMember 2025-01-01 2025-06-30 0001121404 sny:CommercialPaperProgramInUSAMember sny:SanofiEuroMediumTermNotesMember 2025-01-01 2025-06-30 0001121404 sny:EquityInstrumentsIncludedInFinancialAssetsMember ifrs-full:AccumulatedOtherComprehensiveIncomeMember sny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember 2025-01-01 2025-06-30 0001121404 sny:RestrictedSharePlan2024Member 2025-01-01 2025-06-30 0001121404 ifrs-full:IssuedCapitalMember sny:SanofiMember 2025-01-01 2025-06-30 0001121404 sny:MarketedProductsMember 2025-01-01 2025-06-30 0001121404 sny:TechnologicalPlatformsMember 2025-01-01 2025-06-30 0001121404 ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember ifrs-full:ComputerSoftwareMember 2025-01-01 2025-06-30 0001121404 ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember 2025-01-01 2025-06-30 0001121404 ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember sny:AcquiredResearchAndDevelopmentMember 2025-01-01 2025-06-30 0001121404 ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember sny:ProductsTrademarksAndOtherRightsMember 2025-01-01 2025-06-30 0001121404 ifrs-full:ReserveOfSharebasedPaymentsMember 2025-01-01 2025-06-30 0001121404 sny:CommercialPaperProgramInUSAMember 2025-01-01 2025-06-30 0001121404 sny:ForwardCurrencyPurchasesInUSDollarUSBondMember 2025-01-01 2025-06-30 0001121404 sny:CrossCurrencySwapMember 2025-01-01 2025-06-30 0001121404 sny:OpellaBusinessMember 2025-01-01 2025-06-30 0001121404 sny:MSPVaccineCompanyMember sny:MCMVaccineBVMember 2025-01-01 2025-06-30 0001121404 ifrs-full:TreasurySharesMember 2025-01-01 2025-06-30 0001121404 sny:ShareRepurchase2024ProgramMember 2025-01-01 2025-06-30 0001121404 sny:ShareRepurchase2025ProgramMember 2025-01-01 2025-06-30 0001121404 sny:DebtInstrumentsMember ifrs-full:AccumulatedOtherComprehensiveIncomeMember sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember 2025-01-01 2025-06-30 0001121404 ifrs-full:AccumulatedOtherComprehensiveIncomeMember sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember 2025-01-01 2025-06-30 0001121404 sny:InterestRateAndCurrencyDerivativesMember 2025-01-01 2025-06-30 0001121404 sny:EmployeeShareOwnershipPlanMember 2025-01-01 2025-06-30 0001121404 sny:ForeignCurrencyTranslationMember ifrs-full:AccumulatedOtherComprehensiveIncomeMember sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember 2025-01-01 2025-06-30 0001121404 sny:FairValueOnCashFlowHedgesExcludingAssociatesAndJointVenturesMember ifrs-full:AccumulatedOtherComprehensiveIncomeMember sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember 2025-01-01 2025-06-30 0001121404 sny:OpellaMember 2025-01-01 2025-06-30 0001121404 sny:OpellaBusinessMember 2025-01-01 2025-06-30 0001121404 country:AR 2025-06-30 0001121404 country:TR 2025-06-30 0001121404 ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember sny:AcquiredResearchAndDevelopmentMember 2025-06-30 0001121404 ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember sny:ProductsTrademarksAndOtherRightsMember 2025-06-30 0001121404 ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember ifrs-full:ComputerSoftwareMember 2025-06-30 0001121404 ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember 2025-06-30 0001121404 ifrs-full:GrossCarryingAmountMember sny:AcquiredResearchAndDevelopmentMember 2025-06-30 0001121404 ifrs-full:GrossCarryingAmountMember sny:ProductsTrademarksAndOtherRightsMember 2025-06-30 0001121404 ifrs-full:GrossCarryingAmountMember ifrs-full:ComputerSoftwareMember 2025-06-30 0001121404 ifrs-full:GrossCarryingAmountMember 2025-06-30 0001121404 ifrs-full:DebtSecuritiesMember 2025-06-30 0001121404 ifrs-full:TradingEquitySecuritiesMember 2025-06-30 0001121404 ifrs-full:AccumulatedImpairmentMember 2025-06-30 0001121404 ifrs-full:LaterThanOneYearMember 2025-06-30 0001121404 ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember 2025-06-30 0001121404 ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember 2025-06-30 0001121404 ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember 2025-06-30 0001121404 ifrs-full:NotLaterThanOneMonthMember 2025-06-30 0001121404 sny:StockOptionPlanMember ifrs-full:TopOfRangeMember sny:ExercisePriceRangeTwoMember 2025-06-30 0001121404 sny:StockOptionPlanMember ifrs-full:BottomOfRangeMember sny:ExercisePriceRangeTwoMember 2025-06-30 0001121404 sny:StockOptionPlanMember ifrs-full:TopOfRangeMember sny:ExercisePriceRangeFourMember 2025-06-30 0001121404 sny:StockOptionPlanMember ifrs-full:BottomOfRangeMember sny:ExercisePriceRangeFourMember 2025-06-30 0001121404 sny:StockOptionPlanMember ifrs-full:TopOfRangeMember sny:ExercisePriceRangeThreeMember 2025-06-30 0001121404 sny:StockOptionPlanMember ifrs-full:BottomOfRangeMember sny:ExercisePriceRangeThreeMember 2025-06-30 0001121404 sny:ValueOnRedemptionMember 2025-06-30 0001121404 sny:AdjustmentToDebtMeasuredAtFairValueMember 2025-06-30 0001121404 sny:AmortizedCostNettingMember 2025-06-30 0001121404 sny:ForwardCurrencyPurchasesInUnitedArabEmiratesDirhamMember sny:AtNotionalAmountMember 2025-06-30 0001121404 sny:ForwardCurrencyPurchasesInTurkishLiraMember sny:AtNotionalAmountMember 2025-06-30 0001121404 sny:ForwardCurrencyPurchasesInChineseYuanRenminbiMember sny:AtNotionalAmountMember 2025-06-30 0001121404 sny:ForwardCurrencyPurchasesInSingaporeDollarMember sny:AtNotionalAmountMember 2025-06-30 0001121404 sny:ForwardCurrencyPurchasesInUSDollarMember sny:AtNotionalAmountMember 2025-06-30 0001121404 sny:ForwardCurrencyPurchasesMember sny:AtNotionalAmountMember 2025-06-30 0001121404 sny:ForwardCurrencySalesMember sny:ValueOfHedgeRecognizedInEquityMember ifrs-full:CashFlowHedgesMember 2025-06-30 0001121404 sny:ForwardCurrencySalesMember ifrs-full:AtFairValueMember ifrs-full:CashFlowHedgesMember 2025-06-30 0001121404 sny:ForwardCurrencySalesMember sny:AtNotionalAmountMember ifrs-full:CashFlowHedgesMember 2025-06-30 0001121404 sny:ForwardCurrencySalesMember ifrs-full:AtFairValueMember 2025-06-30 0001121404 sny:ForwardCurrencySalesMember sny:AtNotionalAmountMember 2025-06-30 0001121404 sny:AtNotionalAmountMember 2025-06-30 0001121404 ifrs-full:AtFairValueMember sny:NotEligibleForHedgeAccountingMember 2025-06-30 0001121404 sny:ForwardCurrencySalesInPoundSterlingMember sny:AtNotionalAmountMember 2025-06-30 0001121404 sny:ForwardCurrencySalesInJapaneseYenMember sny:AtNotionalAmountMember 2025-06-30 0001121404 sny:ForwardCurrencySalesInChineseYuanRenminbiMember sny:AtNotionalAmountMember 2025-06-30 0001121404 sny:ForwardCurrencySalesInSingaporeDollarMember sny:AtNotionalAmountMember 2025-06-30 0001121404 sny:ForwardCurrencySalesInUSDollarMember sny:AtNotionalAmountMember 2025-06-30 0001121404 sny:ForwardCurrencySalesMember ifrs-full:AtFairValueMember sny:NotEligibleForHedgeAccountingMember 2025-06-30 0001121404 sny:ForwardCurrencySalesMember sny:AtNotionalAmountMember sny:NotEligibleForHedgeAccountingMember 2025-06-30 0001121404 sny:ForwardCurrencySalesInSingaporeDollarMember sny:AtNotionalAmountMember sny:NotEligibleForHedgeAccountingMember 2025-06-30 0001121404 sny:ForwardCurrencySalesInSingaporeDollarMember sny:ValueOfHedgeRecognizedInEquityMember ifrs-full:CashFlowHedgesMember 2025-06-30 0001121404 sny:ForwardCurrencySalesInSingaporeDollarMember ifrs-full:AtFairValueMember ifrs-full:CashFlowHedgesMember 2025-06-30 0001121404 sny:ForwardCurrencySalesInSingaporeDollarMember sny:AtNotionalAmountMember ifrs-full:CashFlowHedgesMember 2025-06-30 0001121404 sny:ForwardCurrencySalesInSingaporeDollarMember ifrs-full:AtFairValueMember 2025-06-30 0001121404 sny:ForwardCurrencySalesInUSDollarMember ifrs-full:AtFairValueMember sny:NotEligibleForHedgeAccountingMember 2025-06-30 0001121404 sny:ForwardCurrencySalesInChineseYuanRenminbiMember sny:AtNotionalAmountMember sny:NotEligibleForHedgeAccountingMember 2025-06-30 0001121404 sny:ForwardCurrencySalesInChineseYuanRenminbiMember sny:ValueOfHedgeRecognizedInEquityMember ifrs-full:CashFlowHedgesMember 2025-06-30 0001121404 sny:ForwardCurrencySalesInChineseYuanRenminbiMember ifrs-full:AtFairValueMember ifrs-full:CashFlowHedgesMember 2025-06-30 0001121404 sny:ForwardCurrencySalesInChineseYuanRenminbiMember sny:AtNotionalAmountMember ifrs-full:CashFlowHedgesMember 2025-06-30 0001121404 sny:ForwardCurrencySalesInChineseYuanRenminbiMember ifrs-full:AtFairValueMember 2025-06-30 0001121404 sny:ForwardCurrencySalesInSingaporeDollarMember ifrs-full:AtFairValueMember sny:NotEligibleForHedgeAccountingMember 2025-06-30 0001121404 sny:ForwardCurrencySalesInJapaneseYenMember sny:AtNotionalAmountMember sny:NotEligibleForHedgeAccountingMember 2025-06-30 0001121404 sny:ForwardCurrencySalesInJapaneseYenMember sny:ValueOfHedgeRecognizedInEquityMember ifrs-full:CashFlowHedgesMember 2025-06-30 0001121404 sny:ForwardCurrencySalesInJapaneseYenMember ifrs-full:AtFairValueMember ifrs-full:CashFlowHedgesMember 2025-06-30 0001121404 sny:ForwardCurrencySalesInJapaneseYenMember sny:AtNotionalAmountMember ifrs-full:CashFlowHedgesMember 2025-06-30 0001121404 sny:ForwardCurrencySalesInJapaneseYenMember ifrs-full:AtFairValueMember 2025-06-30 0001121404 sny:ForwardCurrencySalesInChineseYuanRenminbiMember ifrs-full:AtFairValueMember sny:NotEligibleForHedgeAccountingMember 2025-06-30 0001121404 sny:ForwardCurrencySalesInPoundSterlingMember sny:AtNotionalAmountMember sny:NotEligibleForHedgeAccountingMember 2025-06-30 0001121404 sny:ForwardCurrencySalesInPoundSterlingMember sny:ValueOfHedgeRecognizedInEquityMember ifrs-full:CashFlowHedgesMember 2025-06-30 0001121404 sny:ForwardCurrencySalesInPoundSterlingMember ifrs-full:AtFairValueMember ifrs-full:CashFlowHedgesMember 2025-06-30 0001121404 sny:ForwardCurrencySalesInPoundSterlingMember sny:AtNotionalAmountMember ifrs-full:CashFlowHedgesMember 2025-06-30 0001121404 sny:ForwardCurrencySalesInPoundSterlingMember ifrs-full:AtFairValueMember 2025-06-30 0001121404 sny:ForwardCurrencySalesInJapaneseYenMember ifrs-full:AtFairValueMember sny:NotEligibleForHedgeAccountingMember 2025-06-30 0001121404 sny:ForwardCurrencyPurchasesMember sny:AtNotionalAmountMember sny:NotEligibleForHedgeAccountingMember 2025-06-30 0001121404 sny:ForwardCurrencyPurchasesMember sny:ValueOfHedgeRecognizedInEquityMember ifrs-full:CashFlowHedgesMember 2025-06-30 0001121404 sny:ForwardCurrencyPurchasesMember ifrs-full:AtFairValueMember ifrs-full:CashFlowHedgesMember 2025-06-30 0001121404 sny:ForwardCurrencyPurchasesMember sny:AtNotionalAmountMember ifrs-full:CashFlowHedgesMember 2025-06-30 0001121404 sny:ForwardCurrencyPurchasesMember ifrs-full:AtFairValueMember 2025-06-30 0001121404 sny:ForwardCurrencySalesInPoundSterlingMember ifrs-full:AtFairValueMember sny:NotEligibleForHedgeAccountingMember 2025-06-30 0001121404 sny:ForwardCurrencyPurchasesInUSDollarMember sny:AtNotionalAmountMember sny:NotEligibleForHedgeAccountingMember 2025-06-30 0001121404 sny:ForwardCurrencyPurchasesInUSDollarMember sny:ValueOfHedgeRecognizedInEquityMember ifrs-full:CashFlowHedgesMember 2025-06-30 0001121404 sny:ForwardCurrencyPurchasesInUSDollarMember ifrs-full:AtFairValueMember ifrs-full:CashFlowHedgesMember 2025-06-30 0001121404 sny:ForwardCurrencyPurchasesInUSDollarMember sny:AtNotionalAmountMember ifrs-full:CashFlowHedgesMember 2025-06-30 0001121404 sny:ForwardCurrencyPurchasesInUSDollarMember ifrs-full:AtFairValueMember 2025-06-30 0001121404 sny:ForwardCurrencyPurchasesMember ifrs-full:AtFairValueMember sny:NotEligibleForHedgeAccountingMember 2025-06-30 0001121404 sny:ForwardCurrencyPurchasesInSingaporeDollarMember sny:AtNotionalAmountMember sny:NotEligibleForHedgeAccountingMember 2025-06-30 0001121404 sny:ForwardCurrencyPurchasesInSingaporeDollarMember sny:ValueOfHedgeRecognizedInEquityMember ifrs-full:CashFlowHedgesMember 2025-06-30 0001121404 sny:ForwardCurrencyPurchasesInSingaporeDollarMember ifrs-full:AtFairValueMember ifrs-full:CashFlowHedgesMember 2025-06-30 0001121404 sny:ForwardCurrencyPurchasesInSingaporeDollarMember sny:AtNotionalAmountMember ifrs-full:CashFlowHedgesMember 2025-06-30 0001121404 sny:ForwardCurrencyPurchasesInSingaporeDollarMember ifrs-full:AtFairValueMember 2025-06-30 0001121404 sny:ForwardCurrencyPurchasesInUSDollarMember ifrs-full:AtFairValueMember sny:NotEligibleForHedgeAccountingMember 2025-06-30 0001121404 sny:ForwardCurrencyPurchasesInChineseYuanRenminbiMember sny:AtNotionalAmountMember sny:NotEligibleForHedgeAccountingMember 2025-06-30 0001121404 sny:ForwardCurrencyPurchasesInChineseYuanRenminbiMember sny:ValueOfHedgeRecognizedInEquityMember ifrs-full:CashFlowHedgesMember 2025-06-30 0001121404 sny:ForwardCurrencyPurchasesInChineseYuanRenminbiMember ifrs-full:AtFairValueMember ifrs-full:CashFlowHedgesMember 2025-06-30 0001121404 sny:ForwardCurrencyPurchasesInChineseYuanRenminbiMember sny:AtNotionalAmountMember ifrs-full:CashFlowHedgesMember 2025-06-30 0001121404 sny:ForwardCurrencyPurchasesInChineseYuanRenminbiMember ifrs-full:AtFairValueMember 2025-06-30 0001121404 sny:ForwardCurrencyPurchasesInSingaporeDollarMember ifrs-full:AtFairValueMember sny:NotEligibleForHedgeAccountingMember 2025-06-30 0001121404 sny:ForwardCurrencyPurchasesInTurkishLiraMember sny:AtNotionalAmountMember sny:NotEligibleForHedgeAccountingMember 2025-06-30 0001121404 sny:ForwardCurrencyPurchasesInTurkishLiraMember sny:ValueOfHedgeRecognizedInEquityMember ifrs-full:CashFlowHedgesMember 2025-06-30 0001121404 sny:ForwardCurrencyPurchasesInTurkishLiraMember ifrs-full:AtFairValueMember ifrs-full:CashFlowHedgesMember 2025-06-30 0001121404 sny:ForwardCurrencyPurchasesInTurkishLiraMember sny:AtNotionalAmountMember ifrs-full:CashFlowHedgesMember 2025-06-30 0001121404 sny:ForwardCurrencyPurchasesInTurkishLiraMember ifrs-full:AtFairValueMember 2025-06-30 0001121404 sny:ForwardCurrencyPurchasesInChineseYuanRenminbiMember ifrs-full:AtFairValueMember sny:NotEligibleForHedgeAccountingMember 2025-06-30 0001121404 sny:ForwardCurrencyPurchasesInUnitedArabEmiratesDirhamMember sny:AtNotionalAmountMember sny:NotEligibleForHedgeAccountingMember 2025-06-30 0001121404 sny:ForwardCurrencyPurchasesInUnitedArabEmiratesDirhamMember sny:ValueOfHedgeRecognizedInEquityMember ifrs-full:CashFlowHedgesMember 2025-06-30 0001121404 sny:ForwardCurrencyPurchasesInUnitedArabEmiratesDirhamMember ifrs-full:AtFairValueMember ifrs-full:CashFlowHedgesMember 2025-06-30 0001121404 sny:ForwardCurrencyPurchasesInUnitedArabEmiratesDirhamMember sny:AtNotionalAmountMember ifrs-full:CashFlowHedgesMember 2025-06-30 0001121404 sny:ForwardCurrencyPurchasesInUnitedArabEmiratesDirhamMember ifrs-full:AtFairValueMember 2025-06-30 0001121404 sny:ForwardCurrencyPurchasesInTurkishLiraMember ifrs-full:AtFairValueMember sny:NotEligibleForHedgeAccountingMember 2025-06-30 0001121404 sny:AtNotionalAmountMember sny:NotEligibleForHedgeAccountingMember 2025-06-30 0001121404 sny:ValueOfHedgeRecognizedInEquityMember ifrs-full:CashFlowHedgesMember 2025-06-30 0001121404 ifrs-full:AtFairValueMember ifrs-full:CashFlowHedgesMember 2025-06-30 0001121404 sny:AtNotionalAmountMember ifrs-full:CashFlowHedgesMember 2025-06-30 0001121404 ifrs-full:AtFairValueMember 2025-06-30 0001121404 sny:ForwardCurrencyPurchasesInUnitedArabEmiratesDirhamMember ifrs-full:AtFairValueMember sny:NotEligibleForHedgeAccountingMember 2025-06-30 0001121404 sny:ForwardCurrencySalesInUSDollarMember sny:AtNotionalAmountMember sny:NotEligibleForHedgeAccountingMember 2025-06-30 0001121404 sny:ForwardCurrencySalesInUSDollarMember sny:ValueOfHedgeRecognizedInEquityMember ifrs-full:CashFlowHedgesMember 2025-06-30 0001121404 sny:ForwardCurrencySalesInUSDollarMember ifrs-full:AtFairValueMember ifrs-full:CashFlowHedgesMember 2025-06-30 0001121404 sny:ForwardCurrencySalesInUSDollarMember sny:AtNotionalAmountMember ifrs-full:CashFlowHedgesMember 2025-06-30 0001121404 sny:ForwardCurrencySalesInUSDollarMember ifrs-full:AtFairValueMember 2025-06-30 0001121404 sny:CrossCurrencySellerSwapsInUSDollarMember ifrs-full:LaterThanFiveYearsAndNotLaterThanSevenYearsMember ifrs-full:AtFairValueMember 2025-06-30 0001121404 sny:CrossCurrencySellerSwapsInUSDollarMember ifrs-full:LaterThanFiveYearsAndNotLaterThanSevenYearsMember sny:AtNotionalAmountMember 2025-06-30 0001121404 sny:CrossCurrencySellerSwapsMember ifrs-full:AtFairValueMember 2025-06-30 0001121404 sny:CrossCurrencySellerSwapsMember sny:AtNotionalAmountMember 2025-06-30 0001121404 sny:ForwardCurrencyPurchasesInHungarianFlorintMember ifrs-full:NotLaterThanOneYearMember ifrs-full:AtFairValueMember 2025-06-30 0001121404 sny:ForwardCurrencyPurchasesInHungarianFlorintMember ifrs-full:NotLaterThanOneYearMember sny:AtNotionalAmountMember 2025-06-30 0001121404 sny:ForwardCurrencyPurchasesInUSDollarMember ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember ifrs-full:AtFairValueMember 2025-06-30 0001121404 sny:ForwardCurrencySalesInJapaneseYenMember ifrs-full:NotLaterThanOneYearMember sny:AtNotionalAmountMember 2025-06-30 0001121404 sny:ForwardCurrencySalesInPoundSterlingMember ifrs-full:NotLaterThanOneYearMember ifrs-full:AtFairValueMember 2025-06-30 0001121404 sny:ForwardCurrencySalesInPoundSterlingMember ifrs-full:NotLaterThanOneYearMember sny:AtNotionalAmountMember 2025-06-30 0001121404 sny:ForwardCurrencySalesInUSDollarMember ifrs-full:NotLaterThanOneYearMember ifrs-full:AtFairValueMember 2025-06-30 0001121404 sny:ForwardCurrencySalesInUSDollarMember ifrs-full:NotLaterThanOneYearMember sny:AtNotionalAmountMember 2025-06-30 0001121404 sny:ForwardCurrencyPurchasesInUSDollarMember ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember sny:AtNotionalAmountMember 2025-06-30 0001121404 sny:ForwardCurrencyPurchasesInSingaporeDollarMember ifrs-full:NotLaterThanOneYearMember ifrs-full:AtFairValueMember 2025-06-30 0001121404 sny:ForwardCurrencyPurchasesInSingaporeDollarMember ifrs-full:NotLaterThanOneYearMember sny:AtNotionalAmountMember 2025-06-30 0001121404 sny:ForwardCurrencySalesInJapaneseYenMember ifrs-full:NotLaterThanOneYearMember ifrs-full:AtFairValueMember 2025-06-30 0001121404 sny:NonCurrentLiabilitiesMember sny:ValueOnRedemptionMember 2025-06-30 0001121404 sny:CurrentLiabilitiesMember sny:ValueOnRedemptionMember 2025-06-30 0001121404 sny:OneBillionFiveHundredMillionBondsIssuedInJune2025Member 2025-06-30 0001121404 sny:FixedRateBondMaturingMarch2031Member 2025-06-30 0001121404 sny:FixedRateBondMaturingMarch2027Member 2025-06-30 0001121404 sny:OneBillionFiveHundredMillionBondsIssuedInMarch2025Member 2025-06-30 0001121404 sny:FixedRateBondIssueFromApril2022Member 2025-06-30 0001121404 sny:FixedRateBondIssueFromApril2020Member 2025-06-30 0001121404 sny:FourBillionFacilityMaturingMarch2030Member sny:SanofiEuroMediumTermNotesMember 2025-06-30 0001121404 sny:FourBillionFacilityMaturingDecember2027Member sny:SanofiEuroMediumTermNotesMember 2025-06-30 0001121404 sny:FixedRateBondMaturingMarch2032Member 2025-06-30 0001121404 sny:FixedRateBondMaturingJune2029Member 2025-06-30 0001121404 sny:AtMarketValueMember 2025-06-30 0001121404 country:CN 2025-06-30 0001121404 sny:OtherCountriesExcludingEuropeAndNorthAmericaMember 2025-06-30 0001121404 srt:EuropeMember 2025-06-30 0001121404 country:FR 2025-06-30 0001121404 country:US 2025-06-30 0001121404 sny:BiopharmaSegmentMember 2025-06-30 0001121404 country:GB ifrs-full:PlanAssetsMember 2025-06-30 0001121404 sny:SwedishOrphanBiovitrumABMember ifrs-full:LaterThanFiveYearsMember sny:AntibodiesCollaborationAgreementMember 2025-06-30 0001121404 sny:SwedishOrphanBiovitrumABMember ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember sny:AntibodiesCollaborationAgreementMember 2025-06-30 0001121404 sny:SwedishOrphanBiovitrumABMember sny:AntibodiesCollaborationAgreementMember 2025-06-30 0001121404 sny:CurrentLiabilitiesMember sny:CommercialPaperProgramInFranceMember sny:ValueOnRedemptionMember 2025-06-30 0001121404 sny:CurrentLiabilitiesMember sny:CommercialPaperProgramInUSAMember sny:ValueOnRedemptionMember 2025-06-30 0001121404 sny:InterestRateSwapsPayTwoPointZeroEightPercentReceiveEuriborThreeMMember ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember sny:AtNotionalAmountMember 2025-06-30 0001121404 sny:InterestRateSwapsPayTwoPointZeroEightPercentReceiveEuriborThreeMMember ifrs-full:NotLaterThanOneYearMember sny:AtNotionalAmountMember 2025-06-30 0001121404 sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive1Point17PercentMember sny:ValueOfHedgeRecognizedInEquityMember ifrs-full:CashFlowHedgesMember 2025-06-30 0001121404 sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive1Point17PercentMember sny:AtNotionalAmountMember ifrs-full:FairValueHedgesMember 2025-06-30 0001121404 sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive1Point17PercentMember ifrs-full:AtFairValueMember 2025-06-30 0001121404 sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive1Point17PercentMember sny:AtNotionalAmountMember 2025-06-30 0001121404 sny:InterestRateSwapsPayTwoPointZeroEightPercentReceiveEuriborThreeMMember ifrs-full:AtFairValueMember ifrs-full:CashFlowHedgesMember 2025-06-30 0001121404 sny:InterestRateSwapsPayTwoPointZeroEightPercentReceiveEuriborThreeMMember sny:AtNotionalAmountMember ifrs-full:CashFlowHedgesMember 2025-06-30 0001121404 sny:InterestRateSwapsPayTwoPointZeroEightPercentReceiveEuriborThreeMMember ifrs-full:AtFairValueMember 2025-06-30 0001121404 sny:InterestRateSwapsPayTwoPointZeroEightPercentReceiveEuriborThreeMMember sny:AtNotionalAmountMember 2025-06-30 0001121404 sny:InterestRateSwapsPayTwoPointZeroEightPercentReceiveEuriborThreeMMember ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember sny:AtNotionalAmountMember 2025-06-30 0001121404 sny:InterestRateSwapsPayTwoPointZeroEightPercentReceiveEuriborThreeMMember ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember sny:AtNotionalAmountMember 2025-06-30 0001121404 sny:InterestRateSwapsPayCapitalizedEsterReceive092Member ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember sny:AtNotionalAmountMember 2025-06-30 0001121404 sny:InterestRateSwapsPayCapitalizedEsterReceive092Member ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember sny:AtNotionalAmountMember 2025-06-30 0001121404 sny:InterestRateSwapsPayCapitalizedEsterReceive092Member ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember sny:AtNotionalAmountMember 2025-06-30 0001121404 sny:InterestRateSwapsPayCapitalizedEsterReceive092Member ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember sny:AtNotionalAmountMember 2025-06-30 0001121404 sny:InterestRateSwapsPayCapitalizedEsterReceive092Member ifrs-full:NotLaterThanOneYearMember sny:AtNotionalAmountMember 2025-06-30 0001121404 sny:InterestRateSwapsPayTwoPointZeroEightPercentReceiveEuriborThreeMMember sny:ValueOfHedgeRecognizedInEquityMember ifrs-full:CashFlowHedgesMember 2025-06-30 0001121404 sny:InterestRateSwapsPayCapitalizedEsterReceive092Member ifrs-full:AtFairValueMember ifrs-full:CashFlowHedgesMember 2025-06-30 0001121404 sny:InterestRateSwapsPayCapitalizedEsterReceive092Member sny:AtNotionalAmountMember ifrs-full:CashFlowHedgesMember 2025-06-30 0001121404 sny:InterestRateSwapsPayCapitalizedEsterReceive092Member ifrs-full:AtFairValueMember ifrs-full:FairValueHedgesMember 2025-06-30 0001121404 sny:InterestRateSwapsPayCapitalizedEsterReceive092Member sny:AtNotionalAmountMember ifrs-full:FairValueHedgesMember 2025-06-30 0001121404 sny:InterestRateSwapsPayCapitalizedEsterReceive092Member ifrs-full:AtFairValueMember 2025-06-30 0001121404 sny:InterestRateSwapsPayCapitalizedEsterReceive092Member sny:AtNotionalAmountMember 2025-06-30 0001121404 ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember sny:AtNotionalAmountMember 2025-06-30 0001121404 ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember sny:AtNotionalAmountMember 2025-06-30 0001121404 ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember sny:AtNotionalAmountMember 2025-06-30 0001121404 ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember sny:AtNotionalAmountMember 2025-06-30 0001121404 ifrs-full:NotLaterThanOneYearMember sny:AtNotionalAmountMember 2025-06-30 0001121404 sny:InterestRateSwapsPayCapitalizedEsterReceive092Member sny:ValueOfHedgeRecognizedInEquityMember ifrs-full:CashFlowHedgesMember 2025-06-30 0001121404 ifrs-full:AtFairValueMember ifrs-full:FairValueHedgesMember 2025-06-30 0001121404 sny:AtNotionalAmountMember ifrs-full:FairValueHedgesMember 2025-06-30 0001121404 sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive1Point17PercentMember ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember sny:AtNotionalAmountMember 2025-06-30 0001121404 sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive1Point17PercentMember ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember sny:AtNotionalAmountMember 2025-06-30 0001121404 sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive1Point17PercentMember ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember sny:AtNotionalAmountMember 2025-06-30 0001121404 sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive1Point17PercentMember ifrs-full:NotLaterThanOneYearMember sny:AtNotionalAmountMember 2025-06-30 0001121404 sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive1Point17PercentMember ifrs-full:AtFairValueMember ifrs-full:FairValueHedgesMember 2025-06-30 0001121404 sny:CrossCurrencySwapExpiring2029Member 2025-06-30 0001121404 sny:CrossCurrencySwapExpiring2032Member 2025-06-30 0001121404 sny:ForwardCurrencyPurchasesInUSDollarUSBondMember 2025-06-30 0001121404 sny:ForwardCurrencySalesInUSDollarMember 2025-06-30 0001121404 sny:StockOptionPlanMember 2025-06-30 0001121404 sny:StockOptionPlanMember sny:ExercisePriceRangeTwoMember 2025-06-30 0001121404 sny:StockOptionPlanMember sny:ExercisePriceRangeFourMember 2025-06-30 0001121404 sny:StockOptionPlanMember sny:ExercisePriceRangeThreeMember 2025-06-30 0001121404 sny:RestrictedSharesMember 2025-06-30 0001121404 sny:RestrictedSharePlan2023Member 2025-06-30 0001121404 sny:RestrictedSharePlan2024Member 2025-06-30 0001121404 sny:RestrictedSharePlan2025Member 2025-06-30 0001121404 sny:RestrictedSharePlan2021Member 2025-06-30 0001121404 sny:RestrictedSharePlan2022Member 2025-06-30 0001121404 sny:EuroapiMember 2025-06-30 0001121404 sny:OpellaMember 2025-06-30 0001121404 sny:AssociatesAndJointVenturesMember 2025-06-30 0001121404 sny:MarketedProductsMember 2025-06-30 0001121404 sny:TechnologicalPlatformsMember 2025-06-30 0001121404 sny:CrossCurrencySwapMember 2025-06-30 0001121404 sny:CommercialPaperProgramInUSAMember sny:SanofiEuroMediumTermNotesMember 2025-06-30 0001121404 sny:CommercialPaperProgramInFranceMember sny:SanofiEuroMediumTermNotesMember 2025-06-30 0001121404 sny:ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember 2025-06-30 0001121404 ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflationMember sny:UKZONEMember 2025-06-30 0001121404 ifrs-full:ActuarialAssumptionOfDiscountRatesMember srt:MinimumMember 2025-06-30 0001121404 ifrs-full:ActuarialAssumptionOfDiscountRatesMember srt:MaximumMember 2025-06-30 0001121404 ifrs-full:AggregatedIndividuallyImmaterialAssociatesMember 2025-06-30 0001121404 sny:MSPVaccineCompanyMember 2025-06-30 0001121404 sny:InfraservGmbhAndCoHochstKGMember 2025-06-30 0001121404 sny:ProductLiabilitiesMember sny:ActionForWhichWeAreDefendantMember sny:GoldBondProductLitigationInTheUSMember 2025-06-30 0001121404 sny:OpellaMember 2025-06-30 0001121404 sny:EuroapiMember 2025-06-30 0001121404 sny:CurrentAssetsMember sny:ValueOnRedemptionMember 2025-06-30 0001121404 sny:NonCurrentAssetsMember sny:ValueOnRedemptionMember 2025-06-30 0001121404 sny:AcquiredResearchAndDevelopmentMember 2024-12-31 0001121404 ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember sny:ProductsTrademarksAndOtherRightsMember 2024-12-31 0001121404 ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember ifrs-full:ComputerSoftwareMember 2024-12-31 0001121404 ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember 2024-12-31 0001121404 ifrs-full:GrossCarryingAmountMember 2024-12-31 0001121404 ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember sny:AcquiredResearchAndDevelopmentMember 2024-12-31 0001121404 sny:ProductsTrademarksAndOtherRightsMember 2024-12-31 0001121404 ifrs-full:ComputerSoftwareMember 2024-12-31 0001121404 ifrs-full:GrossCarryingAmountMember sny:AcquiredResearchAndDevelopmentMember 2024-12-31 0001121404 ifrs-full:GrossCarryingAmountMember sny:ProductsTrademarksAndOtherRightsMember 2024-12-31 0001121404 ifrs-full:GrossCarryingAmountMember ifrs-full:ComputerSoftwareMember 2024-12-31 0001121404 ifrs-full:DebtSecuritiesMember 2024-12-31 0001121404 ifrs-full:TradingEquitySecuritiesMember 2024-12-31 0001121404 ifrs-full:AccumulatedImpairmentMember 2024-12-31 0001121404 ifrs-full:LaterThanOneYearMember 2024-12-31 0001121404 ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember 2024-12-31 0001121404 ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember 2024-12-31 0001121404 ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember 2024-12-31 0001121404 ifrs-full:NotLaterThanOneMonthMember 2024-12-31 0001121404 sny:ValueOnRedemptionMember 2024-12-31 0001121404 sny:CurrentLiabilitiesMember sny:ValueOnRedemptionMember 2024-12-31 0001121404 sny:NonCurrentLiabilitiesMember sny:ValueOnRedemptionMember 2024-12-31 0001121404 sny:AtMarketValueMember 2024-12-31 0001121404 srt:EuropeMember 2024-12-31 0001121404 country:CN 2024-12-31 0001121404 country:US 2024-12-31 0001121404 sny:OtherCountriesExcludingEuropeAndNorthAmericaMember 2024-12-31 0001121404 country:FR 2024-12-31 0001121404 sny:OpellaMember 2024-12-31 0001121404 sny:EuroapiMember 2024-12-31 0001121404 sny:AssociatesAndJointVenturesMember 2024-12-31 0001121404 sny:TechnologicalPlatformsMember 2024-12-31 0001121404 sny:MarketedProductsMember 2024-12-31 0001121404 sny:ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember 2024-12-31 0001121404 ifrs-full:AggregatedIndividuallyImmaterialAssociatesMember 2024-12-31 0001121404 sny:MSPVaccineCompanyMember 2024-12-31 0001121404 sny:InfraservGmbhAndCoHochstKGMember 2024-12-31 0001121404 sny:EuroapiMember 2024-12-31 0001121404 sny:CurrentAssetsMember sny:ValueOnRedemptionMember 2024-12-31 0001121404 sny:NonCurrentAssetsMember sny:ValueOnRedemptionMember 2024-12-31 0001121404 ifrs-full:AdditionalPaidinCapitalMember 2024-01-01 2024-06-30 0001121404 ifrs-full:EquityAttributableToOwnersOfParentMember 2024-01-01 2024-06-30 0001121404 sny:ManufacturingAndSupplyMember sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 sny:OpellaMember 2024-01-01 2024-06-30 0001121404 sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 sny:AssociatesAndJointVenturesMember 2024-01-01 2024-06-30 0001121404 sny:RestrictedSharesMember 2024-01-01 2024-06-30 0001121404 ifrs-full:AccumulatedOtherComprehensiveIncomeMember sny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember 2024-01-01 2024-06-30 0001121404 srt:EuropeMember 2024-01-01 2024-06-30 0001121404 country:US 2024-01-01 2024-06-30 0001121404 sny:OtherCountriesMember 2024-01-01 2024-06-30 0001121404 sny:OtherCountriesMember sny:RSVVaccinesMember sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 sny:RSVVaccinesMember sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 srt:EuropeMember sny:InfluenzaVaccinesMember sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 country:US sny:InfluenzaVaccinesMember sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 sny:OtherCountriesMember sny:InfluenzaVaccinesMember sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 sny:InfluenzaVaccinesMember sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 srt:EuropeMember sny:MeningitisTravelAndEndemicVaccinesMember sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 country:US sny:MeningitisTravelAndEndemicVaccinesMember sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 sny:OtherCountriesMember sny:MeningitisTravelAndEndemicVaccinesMember sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 sny:MeningitisTravelAndEndemicVaccinesMember sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 srt:EuropeMember sny:RSVVaccinesMember sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 country:US sny:RSVVaccinesMember sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 sny:OtherCountriesMember sny:IndustrialSalesMember sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 sny:IndustrialSalesMember sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 srt:EuropeMember sny:PolioPertussisHibVaccinesMember sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 country:US sny:PolioPertussisHibVaccinesMember sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 sny:OtherCountriesMember sny:PolioPertussisHibVaccinesMember sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 sny:PolioPertussisHibVaccinesMember sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 srt:EuropeMember sny:TzieldMember sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 country:US sny:TzieldMember sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 sny:OtherCountriesMember sny:TzieldMember sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 sny:TzieldMember sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 srt:EuropeMember sny:IndustrialSalesMember sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 country:US sny:IndustrialSalesMember sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 sny:OtherCountriesMember sny:SarclisaMember sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 sny:SarclisaMember sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 srt:EuropeMember sny:RezurockMember sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 country:US sny:RezurockMember sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 sny:OtherCountriesMember sny:RezurockMember sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 sny:RezurockMember sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 srt:EuropeMember sny:AubagioMember sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 country:US sny:AubagioMember sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 sny:OtherCountriesMember sny:AubagioMember sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 sny:AubagioMember sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 srt:EuropeMember sny:SarclisaMember sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 country:US sny:SarclisaMember sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 sny:OtherCountriesMember sny:CabliviMember sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 sny:CabliviMember sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 srt:EuropeMember sny:XenpozymeMember sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 country:US sny:XenpozymeMember sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 sny:OtherCountriesMember sny:XenpozymeMember sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 sny:XenpozymeMember sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 srt:EuropeMember sny:NexviazymeMember sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 country:US sny:NexviazymeMember sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 sny:OtherCountriesMember sny:NexviazymeMember sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 sny:NexviazymeMember sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 srt:EuropeMember sny:CabliviMember sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 country:US sny:CabliviMember sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 sny:OtherCountriesMember sny:DupixentMember sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 sny:DupixentMember sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 srt:EuropeMember sny:AltuviiioMember sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 country:US sny:AltuviiioMember sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 sny:OtherCountriesMember sny:AltuviiioMember sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 sny:AltuviiioMember sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 srt:EuropeMember sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 country:US sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 sny:OtherCountriesMember sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 srt:EuropeMember sny:DupixentMember sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 country:US sny:DupixentMember sny:BiopharmaSegmentMember 2024-01-01 2024-06-30 0001121404 ifrs-full:ReportableSegmentsMember 2024-01-01 2024-06-30 0001121404 sny:PensionsAndOtherPostEmploymentBenefitsMember ifrs-full:PlanAssetsMember 2024-01-01 2024-06-30 0001121404 sny:OtherOperatingIncomeExpenseMember sny:RegeneronMember 2024-01-01 2024-06-30 0001121404 sny:OtherOperatingIncomeExpenseMember ifrs-full:OtherRelatedPartiesMember 2024-01-01 2024-06-30 0001121404 sny:AntibodiesAllianceMember 2024-01-01 2024-06-30 0001121404 sny:CommercializationRelatedExpensesMember sny:AntibodiesAllianceMember 2024-01-01 2024-06-30 0001121404 sny:ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember sny:AntibodiesAllianceMember 2024-01-01 2024-06-30 0001121404 sny:OtherCountriesExcludingEuropeAndNorthAmericaMember 2024-01-01 2024-06-30 0001121404 country:CN 2024-01-01 2024-06-30 0001121404 country:FR 2024-01-01 2024-06-30 0001121404 ifrs-full:OperatingSegmentsMember 2024-01-01 2024-06-30 0001121404 sny:CustomerOneMember 2024-01-01 2024-06-30 0001121404 sny:CustomerTwoMember 2024-01-01 2024-06-30 0001121404 sny:CustomerThreeMember 2024-01-01 2024-06-30 0001121404 ifrs-full:MaterialReconcilingItemsMember 2024-01-01 2024-06-30 0001121404 sny:ShareOfProfitOrLossFromCommercializationOfZaltrapMember sny:AntibodiesAllianceMember 2024-01-01 2024-06-30 0001121404 sny:CommercializationRelatedExpensesMember ifrs-full:OtherRelatedPartiesMember sny:RegeneronMember 2024-01-01 2024-06-30 0001121404 sny:PensionsAndOtherPostEmploymentBenefitsMember 2024-01-01 2024-06-30 0001121404 sny:PensionsAndOtherPostEmploymentBenefitsMember sny:OpellaBusinessMember 2024-01-01 2024-06-30 0001121404 ifrs-full:AllOtherSegmentsMember 2024-01-01 2024-06-30 0001121404 ifrs-full:IssuedCapitalMember 2024-01-01 2024-06-30 0001121404 ifrs-full:TreasurySharesMember 2024-01-01 2024-06-30 0001121404 ifrs-full:RetainedEarningsMember 2024-01-01 2024-06-30 0001121404 ifrs-full:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-06-30 0001121404 ifrs-full:NoncontrollingInterestsMember 2024-01-01 2024-06-30 0001121404 sny:OthersCounterpartyMember 2024-01-01 2024-06-30 0001121404 sny:EquityInstrumentsIncludedInFinancialAssetsMember ifrs-full:AccumulatedOtherComprehensiveIncomeMember sny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember 2024-01-01 2024-06-30 0001121404 ifrs-full:ReserveOfSharebasedPaymentsMember 2024-01-01 2024-06-30 0001121404 sny:CommercialPaperProgramInUSAMember 2024-01-01 2024-06-30 0001121404 sny:OpellaBusinessMember 2024-01-01 2024-06-30 0001121404 sny:DebtInstrumentsMember ifrs-full:AccumulatedOtherComprehensiveIncomeMember sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember 2024-01-01 2024-06-30 0001121404 ifrs-full:AccumulatedOtherComprehensiveIncomeMember sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember 2024-01-01 2024-06-30 0001121404 sny:InterestRateAndCurrencyDerivativesMember 2024-01-01 2024-06-30 0001121404 sny:EmployeeShareOwnershipPlanMember 2024-01-01 2024-06-30 0001121404 sny:OpellaBusinessMember 2025-04-01 2025-04-30 0001121404 sny:OPALJVCoMember 2025-04-01 2025-04-30 0001121404 sny:OpellaMember 2025-04-01 2025-04-30 0001121404 sny:BpifranceMember 2025-04-01 2025-04-30 0001121404 sny:EarendilLabsMember 2025-04-01 2025-04-30 0001121404 sny:OpellaBusinessMember 2025-04-30 0001121404 sny:VicebioLtdMember 2025-07-22 2025-07-22 0001121404 sny:AssetsAcquisitionMember 2025-05-27 0001121404 sny:AssetsAcquisitionMember 2025-05-27 2025-05-27 0001121404 sny:VigilNeuroscienceIncMember 2025-05-22 2025-05-22 0001121404 sny:VigilNeuroscienceIncMember 2025-05-22 0001121404 sny:BlueprintMedicinesCorporationMember 2025-06-02 0001121404 ifrs-full:IssuedCapitalMember 2024-07-01 2024-12-31 0001121404 ifrs-full:AdditionalPaidinCapitalMember 2024-07-01 2024-12-31 0001121404 ifrs-full:EquityAttributableToOwnersOfParentMember 2024-07-01 2024-12-31 0001121404 ifrs-full:TreasurySharesMember 2024-07-01 2024-12-31 0001121404 ifrs-full:RetainedEarningsMember 2024-07-01 2024-12-31 0001121404 ifrs-full:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-12-31 0001121404 ifrs-full:NoncontrollingInterestsMember 2024-07-01 2024-12-31 0001121404 ifrs-full:ReserveOfSharebasedPaymentsMember 2024-07-01 2024-12-31 0001121404 sny:BiopharmaSegmentMember 2024-06-30 0001121404 sny:RestrictedSharePlan2024Member 2024-06-30 0001121404 sny:RestrictedSharePlan2025Member 2024-06-30 0001121404 sny:RestrictedSharesMember 2024-06-30 0001121404 sny:RestrictedSharePlan2021Member 2024-06-30 0001121404 sny:RestrictedSharePlan2022Member 2024-06-30 0001121404 sny:RestrictedSharePlan2023Member 2024-06-30 0001121404 ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflationMember sny:EUROZONEMember 2024-06-30 0001121404 ifrs-full:ActuarialAssumptionOfDiscountRatesMember srt:MaximumMember 2024-06-30 0001121404 ifrs-full:ActuarialAssumptionOfDiscountRatesMember srt:MinimumMember 2024-06-30 0001121404 sny:ShareRepurchase2024ProgramMember 2025-04-30 2025-04-30 0001121404 sny:ActionForWhichSanofiAreDefendantMember sny:PlavixAttorneyGeneralActionInHawaiiMember 2025-05-01 2025-05-31 0001121404 sny:EarendilLabsMember 2025-04-01 0001121404 sny:ValueOnRedemptionMember 2024-01-01 2024-12-31 0001121404 sny:ForeignCurrencyTranslationMember ifrs-full:AccumulatedOtherComprehensiveIncomeMember sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember 2024-01-01 2024-12-31 0001121404 sny:EmployeeShareOwnershipPlanMember 2025-01-29 0001121404 sny:EmployeeShareOwnershipPlanMember 2024-01-31 0001121404 sny:ShareRepurchase2025ProgramMember 2025-01-29 2025-01-29 0001121404 sny:ShareRepurchase2025ProgramMember 2025-02-02 2025-02-02 0001121404 sny:ShareRepurchase2024ProgramMember 2024-04-30 2024-04-30 0001121404 ifrs-full:ReserveOfSharebasedPaymentsMember 2024-12-31 0001121404 ifrs-full:RetainedEarningsMember 2024-12-31 0001121404 ifrs-full:TreasurySharesMember 2024-12-31 0001121404 ifrs-full:AdditionalPaidinCapitalMember 2024-12-31 0001121404 ifrs-full:IssuedCapitalMember 2024-12-31 0001121404 ifrs-full:NoncontrollingInterestsMember 2024-12-31 0001121404 ifrs-full:EquityAttributableToOwnersOfParentMember 2024-12-31 0001121404 ifrs-full:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001121404 sny:OtherLiabilities1Member 2024-12-31 0001121404 sny:MSDContingentConsiderationEuropeanVaccinesBusinessMember 2024-12-31 0001121404 sny:ProvisionsForOtherLongTermBenefitsMember 2024-12-31 0001121404 sny:NonCurrentRestructuringProvisionMember 2024-12-31 0001121404 ifrs-full:MiscellaneousOtherProvisionsMember 2024-12-31 0001121404 sny:ProvisionsForPensionsAndOtherPostemploymentBenefitsMember 2024-12-31 0001121404 sny:MSDContingentConsiderationEuropeanVaccinesBusinessMember 2025-06-30 0001121404 sny:OtherLiabilities1Member 2025-06-30 0001121404 sny:ProvisionsForPensionsAndOtherPostemploymentBenefitsMember 2025-06-30 0001121404 sny:ProvisionsForOtherLongTermBenefitsMember 2025-06-30 0001121404 sny:NonCurrentRestructuringProvisionMember 2025-06-30 0001121404 ifrs-full:MiscellaneousOtherProvisionsMember 2025-06-30 0001121404 ifrs-full:ReserveOfSharebasedPaymentsMember 2025-06-30 0001121404 ifrs-full:RetainedEarningsMember 2025-06-30 0001121404 ifrs-full:TreasurySharesMember 2025-06-30 0001121404 ifrs-full:AdditionalPaidinCapitalMember 2025-06-30 0001121404 ifrs-full:IssuedCapitalMember 2025-06-30 0001121404 ifrs-full:NoncontrollingInterestsMember 2025-06-30 0001121404 ifrs-full:EquityAttributableToOwnersOfParentMember 2025-06-30 0001121404 ifrs-full:AccumulatedOtherComprehensiveIncomeMember 2025-06-30 0001121404 sny:AcquiredResearchAndDevelopmentMember 2025-06-30 0001121404 sny:ProductsTrademarksAndOtherRightsMember 2025-06-30 0001121404 ifrs-full:ComputerSoftwareMember 2025-06-30 0001121404 ifrs-full:IssuedCapitalMember 2023-12-31 0001121404 ifrs-full:AdditionalPaidinCapitalMember 2023-12-31 0001121404 ifrs-full:TreasurySharesMember 2023-12-31 0001121404 ifrs-full:RetainedEarningsMember 2023-12-31 0001121404 ifrs-full:ReserveOfSharebasedPaymentsMember 2023-12-31 0001121404 ifrs-full:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001121404 ifrs-full:EquityAttributableToOwnersOfParentMember 2023-12-31 0001121404 ifrs-full:NoncontrollingInterestsMember 2023-12-31 0001121404 ifrs-full:IssuedCapitalMember 2024-06-30 0001121404 ifrs-full:AdditionalPaidinCapitalMember 2024-06-30 0001121404 ifrs-full:TreasurySharesMember 2024-06-30 0001121404 ifrs-full:RetainedEarningsMember 2024-06-30 0001121404 ifrs-full:ReserveOfSharebasedPaymentsMember 2024-06-30 0001121404 ifrs-full:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001121404 ifrs-full:EquityAttributableToOwnersOfParentMember 2024-06-30 0001121404 ifrs-full:NoncontrollingInterestsMember 2024-06-30 iso4217:EUR xbrli:pure xbrli:shares iso4217:USD utr:Year utr:Month iso4217:EUR xbrli:shares sny:Proceeding iso4217:USD xbrli:shares
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 6-K
 
 
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
October 27, 2025
Commission File Number: 001-31368
 
 
SANOFI
(Translation of registrant’s name into English)
 
 
46, avenue de la Grande Armée, 75017 Paris, France
(Address of principal executive offices)
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒   Form 40-F ☐
THIS REPORT ON FORM 6-K SHALL BE DEEMED TO BE INCORPORATED BY REFERENCE IN THE REGISTRATION STATEMENT ON FORM F-3 FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON APRIL 4, 2024 (NO. 333-278506) AND REGISTRATION STATEMENT ON FORM S-8 FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON MARCH 27, 2024 (NO. 333- 286161) AND TO BE PART THEREOF FROM THE DATE ON WHICH THIS REPORT IS FURNISHED, TO THE EXTENT NOT SUPERSEDED BY DOCUMENTS OR REPORTS SUBSEQUENTLY FILED OR FURNISHED BY SANOFI.
 
 
 

Exhibit List

 

Exhibit No.

   

Description

Exhibit 99.1    Condensed Half-Year Consolidated Financial Statements for the Six Months Ended June 30, 2025
Exhibit 99.2    Information on H1 2025 Financial Results
Exhibit 99.3    Information on Q3 2025 Financial Results

 

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: October 27, 2025

 

SANOFI

 

By:  

/s/ Alexandra Roger

Name:   Alexandra Roger
Title:   Head of Legal Corporate & Finance

 

3

Source: View Original Filing on SEC EDGAR

Stock SNY logo
Sanofi FR

NASDAQ:SNY

SNY Rankings

#115 Ranked by Market Cap
N/A Ranked by Dividends

SNY Latest News

Oct 16, 2025
EVOQ Therapeutics Announces Collaboration and License Agreement with Sanofi
Oct 2, 2025
Revvity Announces Program to Revolutionize the Early Detection of Type 1 Diabetes
Sep 26, 2025
Sanofi expands patient affordability program by offering access to all its insulins for $35 per month in the US
Sep 10, 2025
Mandy Moore and Celebrity Mom Squad join Sanofi to help protect babies from RSV with BEYFORTUS®
Aug 26, 2025
New Report Highlights Community Health Workers' Impact, Calls for Sustained Local Investment, During National CHW Awareness Week

SNY Latest SEC Filings

Oct 27, 2025
[424B5] Sanofi Prospectus Supplement (Debt Securities)
Oct 24, 2025
[6-K] Sanofi Current Report (Foreign Issuer)
Oct 24, 2025
[6-K] Sanofi Current Report (Foreign Issuer)
Oct 15, 2025
[6-K] – Sanofi (SNY, SNYNF) (CIK 0001121404)
Sep 26, 2025
[6-K] Sanofi Current Report (Foreign Issuer)

SNY Stock Data

125.79B
2.53B
0%
10.28%
0.21%
Drug Manufacturers - General
Healthcare
Link
France
Paris